RxDoctor Payments Data

Douglas Rush, MD

Internal Medicine · Cambridge, OHNPI 1467457846

Payments from drug & device makers

$339in general payments, 2019–2025

Across 20 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$60
  • Pfizer$58
  • AbbVie$55
  • Exact Sciences$44
  • Abbott$26
  • Boehringer Ingelheim$24
  • plus $71 from 4 others

What the payments were for

  • Food & beverage$339100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$339 in reported general payments places this provider in the 60th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$187,445
Medicare patients
304
Services billed
6,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$125,425
OzempicSemaglutide61$91,510
RybelsusSemaglutide32$64,386
JardianceEmpagliflozin27$43,377
TradjentaLinagliptin33$41,344
Tresiba Flextouch U-200Insulin Degludec32$30,554
TrulicityDulaglutide22$26,845
XareltoRivaroxaban19$24,117
MounjaroTirzepatide18$20,464
JanuviaSitagliptin Phosphate17$18,629
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,697
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$6,759
Breo ElliptaFluticasone/Vilanterol17$6,464
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate32$6,061
Fiasp FlextouchInsulin Aspart (Niacinamide)11$5,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$60$155,89693 claims
PfizerEliquis$58$125,425118 claims
Boehringer IngelheimJardiance, Tradjenta$24$84,72060 claims
Lilly USA, LLCTrulicity, Mounjaro$15$47,30940 claims
MerckJanuvia$23$18,62917 claims
AbbVieSynthroid$55$1,98481 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cambridge

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →